Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.

Kelty E, Preen DB.

CNS Drugs. 2019 Nov 4. doi: 10.1007/s40263-019-00681-9. [Epub ahead of print] Review.

PMID:
31686408
2.

Maternal and neonatal health outcomes associated with the use of gliclazide and metformin for the treatment of diabetes in pregnancy: a record linkage study.

Kelty EA, Tran D, Atkinson AA, Preen DB, Havard A.

Diabetes Technol Ther. 2019 Oct 17. doi: 10.1089/dia.2019.0241. [Epub ahead of print]

PMID:
31621408
3.

Familial and non-familial risk factors associated with incidence of colorectal cancer in young and middle-aged persons in Western Australia.

Kelty E, Ward SV, Cadby G, McCarthy NS, O'Leary P, Moses EK, Ee HC, Preen DB.

Cancer Epidemiol. 2019 Oct;62:101591. doi: 10.1016/j.canep.2019.101591. Epub 2019 Sep 5.

PMID:
31494463
4.

Familial and non-familial risk factors associated with colorectal cancer survival in young and middle-aged patients.

Kelty E, Ward SV, Cadby G, McCarthy NS, O'Leary P, Moses EK, Ee HC, Preen DB.

Int J Colorectal Dis. 2019 Oct;34(10):1673-1680. doi: 10.1007/s00384-019-03380-5. Epub 2019 Aug 30.

PMID:
31471697
5.

A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.

Kelty E, Joyce D, Hulse G.

Am J Drug Alcohol Abuse. 2019;45(3):285-291. doi: 10.1080/00952990.2018.1545131. Epub 2019 Mar 8.

PMID:
30848965
6.

Peripheral caries and disease of the periodontium in Western Australian horses: An epidemiological, anatomical and histopathological assessment.

Jackson K, Kelty E, Staszyk C, Tennant M.

Equine Vet J. 2019 Sep;51(5):617-624. doi: 10.1111/evj.13084. Epub 2019 Mar 10.

PMID:
30740768
7.

Prevalence and safety of acamprosate use in pregnant alcohol-dependent women in New South Wales, Australia.

Kelty E, Tran D, Lavin T, Preen DB, Hulse G, Havard A.

Addiction. 2019 Feb;114(2):206-215. doi: 10.1111/add.14429. Epub 2018 Sep 21.

PMID:
30152012
8.

Medical Emergency Team Event Characteristics from an Australian Pediatric Hospital: A Single-Center, Retrospective Study.

Martinez FE, Kelty E, Barr S, McLeod M, Smalley N.

Hosp Pediatr. 2018 Apr;8(4):232-235. doi: 10.1542/hpeds.2017-0185. Epub 2018 Mar 15.

9.

Buprenorphine alone or with naloxone: Which is safer?

Kelty E, Cumming C, Troeung L, Hulse G.

J Psychopharmacol. 2018 Mar;32(3):344-352. doi: 10.1177/0269881118756015. Epub 2018 Feb 13.

10.
11.

Equine peripheral dental caries: An epidemiological survey assessing prevalence and possible risk factors in Western Australian horses.

Jackson K, Kelty E, Tennant M.

Equine Vet J. 2018 Jan;50(1):79-84. doi: 10.1111/evj.12718. Epub 2017 Aug 18.

PMID:
28707363
12.

Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.

Kelty E, Hulse G.

Int J Drug Policy. 2017 Aug;46:54-60. doi: 10.1016/j.drugpo.2017.05.039. Epub 2017 Jun 10.

PMID:
28609749
13.

Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls.

Kelty E, Hulse G.

J Public Health (Oxf). 2018 Jun 1;40(2):409-414. doi: 10.1093/pubmed/fdx063.

PMID:
28591852
16.

Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial.

Martinez FE, Anstey M, Ford A, Roberts B, Hardie M, Palmer R, Choo L, Hillman D, Hensley M, Kelty E, Murray K, Singh B, Wibrow B.

Trials. 2017 Jan 6;18(1):4. doi: 10.1186/s13063-016-1751-0.

17.

Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis.

Cumming C, Troeung L, Young JT, Kelty E, Preen DB.

Drug Alcohol Depend. 2016 Nov 1;168:263-273. doi: 10.1016/j.drugalcdep.2016.10.001. Epub 2016 Oct 6. Review.

PMID:
27736680
18.

Erratum to "Emergency department based intervention with adolescent substance users: 10year economic and health outcomes" [Drug Alcohol Depend. 165 (2016) 168-174].

Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK.

Drug Alcohol Depend. 2016 Oct 1;167:236. doi: 10.1016/j.drugalcdep.2016.08.005. Epub 2016 Aug 8. No abstract available.

PMID:
27515724
19.

Emergency department based intervention with adolescent substance users: 10year economic and health outcomes.

Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK.

Drug Alcohol Depend. 2016 Aug 1;165:168-74. doi: 10.1016/j.drugalcdep.2016.06.005. Epub 2016 Jun 11.

PMID:
27317044
20.

Idiopathic interstitial pneumonia in the ICU: an observational cohort.

Martinez FE, Panwar R, Kelty E, Smalley N, Williams C.

Anaesth Intensive Care. 2015 Nov;43(6):707-11.

21.

Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System.

Hulse G, Kelty E, Hood S, Norman A, Basso MR, Reece AS.

Curr Pharm Des. 2015;21(23):3325-42. Review.

PMID:
26088116
22.

Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1.

Hancock DB, Levy JL, Gaddis NC, Glasheen C, Saccone NL, Page GP, Hulse GK, Wildenauer D, Kelty EA, Schwab SG, Degenhardt L, Martin NG, Montgomery GW, Attia J, Holliday EG, McEvoy M, Scott RJ, Bierut LJ, Nelson EC, Kral AH, Johnson EO.

Biol Psychiatry. 2015 Oct 1;78(7):474-84. doi: 10.1016/j.biopsych.2015.01.003. Epub 2015 Jan 29.

23.
24.

Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol use.

Kelty E, Hayes L, O'Neil G, Kyle S, Jeffrey GP, O'Neil G, Hendrie D, Mukhtar A, Hulse G.

J Psychopharmacol. 2014 Aug;28(8):745-50. doi: 10.1177/0269881114536791. Epub 2014 Jun 5.

PMID:
24902873
25.

Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report.

Kelty E, Martyn V, O'Neil G, Hulse G.

J Psychopharmacol. 2014 Jul;28(7):703-6. doi: 10.1177/0269881114523865. Epub 2014 Feb 19.

PMID:
24554692
26.

A retrospective assessment of the use of naltrexone implants for the treatment of problematic amphetamine use.

Kelty E, Thomson K, Carlstein S, Sinclair R, Hulse G.

Am J Addict. 2013 Jan;22(1):1-6. doi: 10.1111/j.1521-0391.2013.00320.x.

PMID:
23398219
27.
28.

Developmental cigarette smoke exposure: liver proteome profile alterations in low birth weight pups.

Canales L, Chen J, Kelty E, Musah S, Webb C, Pisano MM, Neal RE.

Toxicology. 2012 Oct 9;300(1-2):1-11. doi: 10.1016/j.tox.2012.04.016. Epub 2012 May 15.

29.

Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.

Kelty E, Hulse G.

Addiction. 2012 Oct;107(10):1817-24. doi: 10.1111/j.1360-0443.2012.03910.x. Epub 2012 May 17.

PMID:
22487087
30.

Environmental cigarette smoke exposure modulates IgE levels of Pb-exposed children.

Lutz PM, Kelty EA, Brown TD, Wilson TJ, Brock G, Neal RE.

Toxicology. 2012 Jan 27;291(1-3):43-50. doi: 10.1016/j.tox.2011.10.013. Epub 2011 Oct 25.

31.

Abstractness and continuity in the syntactic development of young children with autism.

Naigles LR, Kelty E, Jaffery R, Fein D.

Autism Res. 2011 Dec;4(6):422-37. doi: 10.1002/aur.223. Epub 2011 Oct 19.

32.

6-month use of 0.2% delmopinol hydrochloride in comparison with 0.2% chlorhexidine digluconate and placebo (II). Effect on plaque and salivary microflora.

Hase JC, Edwardsson S, Rundegren J, Attström R, Kelty E.

J Clin Periodontol. 1998 Nov;25(11 Pt 1):841-9.

PMID:
9846791
33.
34.

Plaque formation and gingivitis after supervised mouthrinsing with 0.2% delmopinol hydrochloride, 0.2% chlorhexidine digluconate and placebo for 6 months.

Lang NP, Hase JC, Grassi M, Hämmerle CH, Weigel C, Kelty E, Frutig F.

Oral Dis. 1998 Jun;4(2):105-13.

PMID:
9680899
35.

A 6-month home-usage trial of 0.1% and 0.2% delmopinol mouthwashes (I). Effects on plaque, gingivitis, supragingival calculus and tooth staining.

Claydon N, Hunter L, Moran J, Wade W, Kelty E, Movert R, Addy M.

J Clin Periodontol. 1996 Mar;23(3 Pt 1):220-8.

PMID:
8707981
36.

The efficacy of Decapinol mouthwash 2 mg/mL in preventing gingivitis.

Yeung S, Groenlund C, Chapple C, Kemm A, Spencer R, Grossberg D, Newell P, Fitzpatrick J, Kelty E, Movert R.

Aust Dent J. 1995 Aug;40(4):220-5.

PMID:
7575274
37.

A 6-month home-usage trial of 0.1% and 0.2% delmopinol mouthwashes (II). Effects on the plaque microflora.

Elworthy AJ, Edgar R, Moran J, Addy M, Movert R, Kelty E, Wade WG.

J Clin Periodontol. 1995 Jul;22(7):527-32.

PMID:
7560235
38.

Development of plaque and gingivitis after mouthrinsing with 0.2% delmopinol hydrochloride.

Hase JC, Söder PO, Söder B, Kulstad S, Kelty E.

Eur J Oral Sci. 1995 Jun;103(3):172-8.

PMID:
7634133
39.

Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients.

Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A, et al.

Br J Surg. 1995 Apr;82(4):496-501.

PMID:
7613894
40.

Half-past tomorrow.

Kelty EJ.

J Allied Health. 1981 Aug;10(3):149-53. No abstract available.

PMID:
7263502
41.

Mental health in health planning: fitting square programs into round wholes?

Kelty EJ.

Am J Health Plann. 1978 Jul;3(3):65-70.

PMID:
10308628
42.

Is services integration dangerous to your mental health?

Kelty EJ.

Evaluation. 1976;3(1-2):139-41, 159. No abstract available.

PMID:
1028602
43.

Psychological functioning of aged individuals with normal and abnormal electroencephalograms. I. A study of non-hospitalized community volunteers.

BUSSE EW, BARNES RH, FRIEDMAN EL, KELTY EJ.

J Nerv Ment Dis. 1956 Aug;124(2):135-41. No abstract available.

PMID:
13416928

Supplemental Content

Support Center